Ionis Pharmaceuticals (IONS) just received U.S. FDA approval for ZANVASTRO, an RNA targeted treatment for Alexander disease in pediatric and adult patients. The stock now reflects a new approved rare disease asset.
Even with the FDA approval for ZANVASTRO, Ionis Pharmaceuticals shares have been under pressure in the near term, with the 1-day share price return down 5.22% and the 7-day share price return down 6.89%. The 30-day share price return is up 5.56% from a weaker base, and the year-to-date share price return is down 27.04% at a last close of US$58.13. Despite that recent softness, longer term momentum in total shareholder return has been stronger than the short-term picture, with the 3-year total shareholder return at 43.96% and the 5-year total shareholder return at 60.31%.
Compare how Ionis Pharmaceuticals stacks up against other rare disease players by reviewing the hand picked 21 high quality undiscovered gems that are already on many investors' watchlists.
Ionis Pharmaceuticals now trades at a steep discount to both intrinsic estimates and analyst targets after the ZANVASTRO approval. Is that discount an opportunity, or a sign that the market's caution is warranted?
Most Popular Narrative: 34% Undervalued
Ionis Pharmaceuticals last closed at $58.13 while the most followed narrative anchors fair value at $88.00. That gap rests on some very specific growth expectations.
The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.
Expanding addressable patient populations, from rare diseases to larger segments like severe hypertriglyceridemia (sHTG), combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.
Want to see what sits behind that growth arc for Ionis Pharmaceuticals? The narrative leans on fast revenue expansion, rising margins and a rich future earnings multiple. Curious which specific forecasts need to land for $88 to hold up.
Result: Fair Value of $88.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Ionis Pharmaceuticals also carries clear risks, including heavy reliance on a few late stage programs and potential pricing pressure as it expands into broader patient groups.
Find out about the key risks to this Ionis Pharmaceuticals narrative.
Next Steps
Given the mix of optimism and caution around Ionis Pharmaceuticals, it makes sense to move quickly and review the underlying data yourself. You can start by weighing those potential upsides in the 2 key rewards .
Looking for more investment ideas beyond Ionis Pharmaceuticals?
If Ionis Pharmaceuticals has your attention, do not stop here. Some of the most compelling opportunities often sit just outside your current watchlist.
-
Target potential upside by scanning companies that screen as 52 high quality undervalued stocks before the crowd focuses on them.
-
Protect your capital by reviewing a 79 resilient stocks with low risk scores that highlights businesses with more resilient profiles.
-
Strengthen your watchlist by checking the list of solid balance sheet and fundamentals (53 results) so you are not caught off guard by fragile finances.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include IONS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
